

Last updated: Jan. 2022.

Mary Ann Liebert, Inc.  publishers

**Biotechnology
and
Regenerative
Medicine**



**Biomedical
Research**



**Clinical
Medicine**



**Engineering
and
Technology**



**Environmental Studies
Integrative Medicine
Law and Policy
Nursing
Public Health
Surgery**



The Leading Independent Publisher of Specialty STM content

<https://www.liebertpub.com/>

EBSCO

EBSCO Korea



About **Mary Ann Liebert**

- 주제분야 : AIDS, 유전자 치료, 생명의학, 공학, 임상의학, 법학, 환경과학
- 원문정보 제공 년도 : 1980년 - 현재 (저널 별로 다양)
- 저널종수 : 기본 (73 종) / 신규 타이틀 패키지 (18종)
- 서비스제공주소 : <https://www.liebertpub.com>

Mary Ann Liebert, Inc. publishers

- ① 1980년에 설립되어 AIDS, 유전자 치료, 생물복제 등의 전문분야를 다룸.
- ② 생물공학 분야에서 주도적인 출판사로 손꼽히고 있음.

Mary Ann Liebert, Inc. publishers




Site Navigation

사이트 소개



Responsive Design

모바일 기기
반응형 웹 지원



별도의 어플리케이션
다운로드 없이
어떠한 기기에서도
Mary Ann Liebert
모든 콘텐츠에 대하여
쉽게 접근이 가능함.




Main Page

개인 계정으로 로그인 가능

특정 콘텐츠 검색이 가능함

홈페이지 내 어디서든지 로고를 누르면
다시 메인 페이지로 돌아갑니다.



“Publication” 메뉴에 마우스를 가져가면 드롭-다운메뉴가 아래와 같이 제공됨

Publications
drop-down
menu
발간물

The screenshot shows the Mary Ann Liebert, Inc. website. The top navigation bar is dark red with the following links: PUBLICATIONS (highlighted with a yellow circle), AUTHORS, LIBRARIANS, OPEN ACCESS, ADVERTISING, and CORPORATE CAPABILITIES. Below the navigation bar, there are three main sections: Journal Collections, Publications by Type, and All Publications. The Journal Collections section lists various fields of study. The Publications by Type section lists different types of publications. The All Publications section has a link to 'Recommend a Title to Your Library'. A red arrow points from the '모든 발간물과 A-Z 디렉토리' text to the 'All Publications' section. At the bottom of the page, there are four sections: Authors, Librarians, Open Access, and Corporate Capabilities. The Windows taskbar at the bottom shows the date and time as 9:08 AM 4/24/2018.

Mary Ann Liebert, Inc. publishers

컬렉션 단위

타입별

PUBLICATIONS

AUTHORS

LIBRARIANS

OPEN ACCESS

ADVERTISING

CORPORATE CAPABILITIES

Journal Collections

Publications by Type

All Publications

모든 발간물과 A-Z 디렉토리

Authors

Librarians

Open Access

Corporate Capabilities



Methods of Browsing Our Journals

컬렉션/ A-Z/ 유형별 브라우징 가능

The screenshot shows the Mary Ann Liebert, Inc. publishers website. The header includes the logo and navigation links: PUBLICATIONS, AUTHORS, LIBRARIANS, OPEN ACCESS, ADVERTISING, and CORPORATE CAPABILITIES. Below the header, there's a navigation bar with links: PUBLICATIONS, PUBLICATIONS A-Z, JOURNAL COLLECTIONS, PUBLICATION BY TYPE, and RECOMMEND A TITLE. The main content area features a banner for 'Groundbreaking Publications' with a description of the portfolio. Below the banner, there's a section titled 'Browse our complete catalog or by subject area to learn more about our unparalleled publications'. This section contains three overlapping circles, each representing a browsing method: 'Journal Collections', 'Titles A-Z', and 'Publications by Type'. Each circle has a brief description and a link to browse. The 'Journal Collections' circle is highlighted with a red circle. The 'Titles A-Z' circle is highlighted with a red circle. The 'Publications by Type' circle is highlighted with a red circle.

Groundbreaking Publications
Our portfolio of peer-reviewed journals, trade magazines, books, and newsletters delivers critical, trusted information across the fields of science, technology, engineering, and medicine.

Browse our complete catalog or by subject area to learn more about our unparalleled publications

- Journal Collections**
More than 90 peer-reviewed journals in the most promising areas of biomedical research, biotechnology and regenerative medicine, clinical medicine and surgery, public health, technology and engineering, environmental studies, and law and policy.
[Browse collections...](#)
- Titles A-Z**
View the complete alphabetized catalog of Mary Ann Liebert publications with direct access to in-depth publication information and published content.
[Browse A-Z...](#)
- Publications by Type**
In addition to our industry leading peer-reviewed journals, the full Mary Ann Liebert catalog of publications includes books, ebooks, trade magazines, newsletters, and more!
[Browse by type...](#)

Mary Ann Liebert 출판사의 content 를
학술분야, A to Z, Content 타입 별로
브라우징 가능하도록 화면 구성
각 메뉴에 쉽게 접근할 수 있도록 구성



Browse by Collections

저널 컬렉션

생물의학, 생명공학, 약학, 환경 연구, 정책, 법, 보건환경, 간호, 임상의학, 공학기술, 수술 등 주제분야별 저널 브라우징 가능

PUBLICATIONS PUBLICATIONS A- JOURNAL COLLECTIONS PUBLICATION

Mary Ann Liebert Journal Collections

More than 90 peer-reviewed journals in the most promising areas of biomedical research, biotechnology and regenerative medicine, clinical medicine and surgery, public health, technology and engineering, environmental studies, and law and policy.

Biotechnology and Regenerative Medicine	Biomedical Research	Clinical Medicine	Technology and Engineering
Integrative Medicine	Law and Policy	Nursing	Public Health
	Surgery	Environmental Studies	

Call us toll free (800) M-LIEBERT



Browse Journals A - Z

A-Z List

PUBLICATIONS PUBLICATIONS A-Z JOURNAL COLLECTIONS PUBLICATION BY TYPE RECOMMEND A TITLE

Publication List A-Z

Titles beginning with: 3 | A | B | C | D | E | F | G | H | I | J | L | M | N | O | P | R | S | T | V | W | Z | Show All

19 Articles You Can Use: Series of Planned Giving	MORE INFO	이용상태 확인
3D Printing and Additive Manufacturing	MORE INFO	ONLINE ACCESS
Advances in Preschool Psychopharmacology	MORE INFO	ONLINE ACCESS
Advances in Preschool Psychopharmacology: e-Book	MORE INFO	
Advances in Tissue Engineering, Volume 1: Angiogenesis	MORE INFO	ONLINE ACCESS
Advances in Tissue Engineering, Volume 1: e-book	MORE INFO	
Advances in Tissue Engineering, Volume 2: e-book	MORE INFO	
Advances in Tissue Engineering, Volume 2: Stem Cells	MORE INFO	ONLINE ACCESS
Advances in Wound Care	MORE INFO	ONLINE ACCESS
Advances in Wound Care, Volume 1	MORE INFO	ONLINE ACCESS
Advances in Wound Care, Volume 2	MORE INFO	ONLINE ACCESS
Advances in Wound Care, Volume 2 e-book	MORE INFO	
Advances in Wound Care: Volume 1: e-book	MORE INFO	
AIDS Patient Care and STDs	MORE INFO	ONLINE ACCESS
AIDS Research and Human Retroviruses	MORE INFO	ONLINE ACCESS


More Info를 클릭하면
저널 상세페이지로 이동

이용상태 확인



Browse by Type

타입별



저널, 단행본, eBook, 뉴스레터 등
자료 형태별 브라우징 가능




Search 검색




Search

Mary Ann Liebert 사이트 내 어디서든 우측 상단의 돋보기 모양을 클릭하면 아래와 같은 검색창이 나타남



The screenshot shows the top navigation bar of the Mary Ann Liebert website. On the left is the logo "Mary Ann Liebert, Inc. publishers" with a stylized leaf icon. On the right, it says "brought to you by Mary Ann Liebert, Inc., publishers" followed by a magnifying glass icon, a user icon, and a shopping cart icon. Below this, a horizontal menu contains the following links: PUBLICATIONS, AUTHORS, LIBRARIANS, OPEN ACCESS, ADVERTISING, and CORPORATE CAPABILITIES. A red arrow points from the text above to the magnifying glass icon in the top right corner.

- 사이트 내 모든 곳과 인용 등 선택하여 검색이 가능
- 단어/ 문구/ DOI / ISBN/ 키워드 / 저자 등의 검색을 할 수 있음



This screenshot shows the advanced search interface. It features a dark red header with the same logo and navigation menu as the previous screenshot. Below the header, there is a search bar with a dropdown menu on the left showing "Anywhere" and a search button on the right. To the right of the search bar is a link to "Advanced Search". Below the search bar, there are several input fields for "Citation", "Journal", "Year", "Volume", "Issue", and "Page", each with a dropdown arrow. A red arrow points from the text below to the "Advanced Search" link.

더 나은 검색결과를 위하여 Advanced 검색



Advanced Search – 상세검색

Mary Ann Liebert, Inc. publishers

검색기록 / 저장된 검색결과 확인

PUBLICATIONS AUTHOR

Advanced Search Search History Saved Searches

모두/ 서명/ 저자/ 주제어/ 초록 등을 선택하여 검색

Anywhere

Anywhere

Title

Author

Keywords

Abstract

Enter Search term And / Or / Not 연산자 활용 가능

+

추가 검색 조건을 넣을 수 있음

e.g. Journal of Theoretical Biology 저널명 등을 입력할 수 있음

All dates

Last Select

Custom range Month Year Month Year

출판 년도 한정 검색

Advanced

include Articles in Ahead of Print

이미 출판된 논문을 포함하여 검색할 것인지 선택

Search



Search Results


클릭하여
검색결과를 저장

The screenshot shows the search results page for 'Genetic Editing' on the Mary Ann Liebert, Inc. website. The page is divided into several sections:

- Header:** Mary Ann Liebert, Inc. publishers logo and navigation links (PUBLICATIONS, AUTHORS, LIBRARIANS, OPEN ACCESS, ADVERTISING).
- Search Bar:** A search bar with the text 'Genetic Editing' and a dropdown menu set to 'Anywhere'. An 'Advanced Search' link is also present.
- Filters:** A sidebar on the left titled 'NARROW RESULTS' showing 'FILTERS APPLIED' (Last Year) and a list of article types with counts: Research Article (255), Review Article (50), Editorial (27), Letter (17), Abstract (12), and MORE (6). Below this is an 'AUTHOR' section listing authors like Flotte, Terence R (11), Wilson, James M (6), Davies, Kevin (5), and Philiniridis, Alex (5).
- Results:** The main content area shows 'RESULTS: 1 - 20 of 383 Genetic Editing'. It includes a 'REFINE SEARCH' dropdown, 'PER PAGE' options (20, 50, 100), and a 'SORT: RELEVANCE' dropdown. The results list includes:
 - Recent Advances in Therapeutic Genome Editing in China** by Yang Yang, Wang Qingnan, Li Qian, Men Ke, He Zhiyao, Deng Hongxin, Ji Weizhi, Wei Yuquan. Published Online: 01 Feb 2018 | <https://doi.org/10.1089/hum.2017.210>
 - Transgenerational CRISPR-Cas9 Activity Facilitates Multiplex Gene Editing in Allopolyploid Wheat** by Wang Wei, Pan Qianli, He Fei, Akhunova Alina, Chao Shiaoan, Trick Harold, Akhunov Eduard. Published Online: 01 Feb 2018 | <https://doi.org/10.1089/crispr.2017.0010>
 - Adenosine-to-Inosine RNA Editing in Health and Disease** by Gatsiou Aikaterini, Vlachogiannis Nikolaos, Lunella Federica Francesca, Sachse Marco, Stellos Konstantinos. Published Online: 01 Feb 2018 | <https://doi.org/10.1089/hum.2017.210>



Refine Search – 결과 내 검색



The screenshot shows a search results interface. On the left, under 'NARROW RESULTS', there are filters applied: 'Review Article' and 'Last Year'. Below this, a list of authors is shown with counts: Chuah, Marinee K (2), Dandara, Collet (2), Kunej, Tanja (2), VandenDriessche, Thierry (2), and Abuharfeil, Nizar Mohammad (1). There is also a 'PUBLICATION' section with a list of topics and counts. On the right, the main search results area shows 'RESULTS: 1 - 20 of 50 Genetic Editing'. A red arrow points to the 'REFINE SEARCH' button. Below this, there are 'Advanced Options' including 'Search History' and 'Saved Searches'. The search criteria are displayed: 'Anywhere' (dropdown), 'Genetic Editing' (text input), 'Anywhere' (dropdown), 'Enter Search term' (text input), 'Published in' (dropdown with 'e.g. Bioelectronics in Medicine'), and 'Publication Date' (radio buttons for 'All dates', 'Last' (selected), and 'Custom range' with month/year dropdowns). A 'Search' button is at the bottom right.

NARROW RESULTS

FILTERS APPLIED

Review Article × Last Year ×

Clear all

AUTHOR

Chuah, Marinee K 2

Dandara, Collet 2

Kunej, Tanja 2

VandenDriessche, Thierry 2

Abuharfeil, Nizar Mohammad 1

MORE (95) ▾

PUBLICATION

Human Gene Therapy Clinical Development 18

Human Gene Therapy Methods 18

Human Gene Therapy 16

Antioxidants & Redox Signaling 8

The CRISPR Journal 4

TITLES AND WEBSITE RESULTS

ARTICLES AND PUBLISHED CONTENT

RESULTS: 1 - 20 of 50 Genetic Editing

Follow results: 🔍 📡

REFINE SEARCH ▾

PER PAGE: 20 50 100 | SORT: RELEVANCE ▾

Advanced Options Search History Saved Searches

Anywhere ▾ Genetic Editing +

Anywhere ▾ Enter Search term +

Published in e.g. Bioelectronics in Medicine

Publication Date

☐ All dates


☒ Last year ▾

☐ Custom range Month ▾ Year ▾ Month ▾ Year ▾


Search



Search History – 검색 히스토리



Saved Searches – 검색결과 저장



[PUBLICATIONS](#) [AUTHORS](#) [LIBRARIANS](#) [OPEN ACCESS](#) [ADVANCED SEARCH](#)

[Advanced Search](#) [Search History](#) [Saved Searches](#)

Saved Search Name	Frequency	Last run on		
Genetic Editing	D	May 1, 2018	RUN	DELETE



Journal Pages

저널



Journal Landing Page

개별 저널 페이지

A

B

C

D

E

F



Journal of Neurotrauma

Editor-in-Chief: John T. Povlishock, PhD

ISSN: 0897-7151 | Online ISSN: 1557-9042 | 24 Issues Annually | Current Volume: 35

Latest Impact Factor* is **5.190** *2016 Journal Citation Reports® (Clarivate Analytics, 2017)

The only peer-reviewed journal focused exclusively on traumatic brain and spinal cord injury, with far-reaching coverage ranging from the basic biology of trauma to clinical trials aimed at improving long-term care and recovery...

[View Aims & Scope...](#)

Search



Subscribe/Renew



Recommend This Title



Sign Up for TOC Alerts



Submit a Paper



Share with a Colleague



A 현재 발간 이슈

B 모든 이슈

C 구독/갱신 관련

D 논문 투고 관련 정보

E 알람 설정

F 광고 관련

Featured Content

PRESS

Does Concussion Recovery and Symptom Severity Differ Between Men and Women?

[READ MORE](#)

PRESS

Best Practices Lacking for Managing Traumatic Brain Injury in Geriatric Patients




Current
Issue
Journal View
현재 발간
이슈

Mary Ann Liebert, Inc. publishers

PUBLICATIONS AUTHORS LIBRARIANS OPEN ACCESS

PUBLICATION HOME SUBSCRIBE/ORDER FOR AUTHORS ALERTS ADVERTISE



Journal of Neurotrauma

Editor-in-Chief: John T. Povlishock, PhD

ISSN: 0897-7151 | Online ISSN: 1557-9042 | 24 Issues Annually | Current Volume: 35

Latest Impact Factor* is 5.19 *2016 Journal C

최신 Impact Factor 확인

The only peer-reviewed journal focused exclusively on traumatic brain and spinal cord injury, with far-reaching coverage ranging from the basic biology of trauma to clinical trials aimed at improving long-term care and recovery.

Submit a Paper 논문 투고

Subscribe/Renew 구독 및 갱신

All Issues 모든 이슈

Reprints/ePrints

VOLUME 35, ISSUE 9 / MAY 2018

액세스 여부 확인

Open Access

Rho Inhibitor VX-210 in Acute Traumatic Subaxial Cervical Spinal Cord Injury: Design of the SPinal Cord Injury Rho INhibition InvestiGation (SPRING) Clinical Trial

Fehlings Michael G., Kim Kee D., Aarabi Bizhan, Rizzo Marco, Bond Lisa M., McKerracher Lisa, Vaccaro Alexander R., and Okonkwo David O.

Pages: 1049–1056 | Published Online: 1 March 2018

<https://doi.org/10.1089/neu.2017.5434>

원문 / PDF 저장

Preview Abstract Abstract Full text PDF Permissions

Parallel Evaluation of Two Potassium Channel Blockers in Restoring Conduction in Mechanical Spinal Cord

<https://serve.liebertpub.com/link/NEU/5/252/7804/8818/192.168.2.101/>

SECURE YOUR ACCESS TO
Journal of Neurotrauma
REQUEST A SUBSCRIPTION

Author Benefits Program
Mary Ann Liebert, Inc.



Article Pages

아티클





Figures



References



Related



Details

Rho Inhibitor VX-210 in Acute Traumatic Subaxial Cervical Spinal Cord Injury: Design of the SPinal Cord Injury Rho INhibition InvestiGation (SPRING) Clinical Trial

Fehlings Michael G., Kim Kee D., Aarabi Bizhan, Rizzo Marco, Bond Lisa M., McKerracher Lisa, Vaccaro Alexander R., and Okonkwo David O.

Published Online: 1 May 2018 | <https://doi.org/10.1089/neu.2017.5434>

목차 / 원문보기

Sections View Article


추천 & 공유

Tools Share

Abstract 초록

Traumatic spinal cord injury (SCI) is associated with a lifetime of disability stemming from loss of motor, sensory, and autonomic functions; these losses, along with increased comorbid sequelae, negatively impact health outcomes and quality of life. Early decompression surgery post-SCI can enhance patient outcomes, but does not directly facilitate neural repair and regeneration. Currently, there are no U.S. Food and Drug Administration–approved pharmacological therapies to augment motor function and functional recovery in individuals with traumatic SCI. After an SCI, the enzyme, Rho, is activated by growth-inhibitory factors and regulates events that culminate in collapse of the neuronal growth cone, failure of axonal regeneration, and, ultimately, failure of motor and functional recovery. Inhibition of Rho activation is a potential treatment for injuries such as traumatic SCI. VX-210, an investigational agent, inhibits Rho. When administered extradurally after decompression (corpectomy or laminectomy) and stabilization surgery in a phase 1/2a study, VX-210 was well tolerated. Here, we describe the design of the SPRING trial, a multicenter, phase 2b/3, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of VX-210 (NCT02669849). A subset of patients with acute traumatic cervical SCI is currently being enrolled in the United States and Canada. Medical, neurological, and functional changes are evaluated at 6 weeks and at 3, 6, and 12 months after VX-210 administration. Efficacy will be assessed by the primary outcome measure, change in upper extremity motor score at 6 months post-treatment, and by secondary outcomes that include question-based and task-based evaluations of functional recovery.

수치,도표 /참고문헌 / 관련자료/ 논문정보



VOLUME 35, ISSUE 9
MAY 2018

Information

© Michael G. Fehlings et al.

논문관련 정보

To cite this article:

Fehlings Michael G., Kim Kee D., Aarabi Bizhan, Rizzo Marco, Bond Lisa M., McKerracher Lisa, Vaccaro Alexander R., and Okonkwo David O..

Journal of Neurotrauma. May 2018. ahead of print

<http://doi.org/10.1089/neu.2017.5434>



Published in Volume: 35 Issue 9: May 1, 2018

Online Ahead of Print: March 1, 2018

Online Ahead of Editing: January 9, 2018

Keywords

관련 키워드

motor recovery

Rho inhibition

spinal cord injury

SPRING trial

VX-210

Publication History

Published online 1 May 2018





Rho Inhibitor VX-210 in Acute Traumatic Subaxial Cervical Spinal Cord Injury: Design of the SPinal Cord Injury Rho INhibition InvestiGation (SPRING) Clinical Trial

Fehlings Michael G., Kim Kee D., Aarabi Bizhan, Rizzo Marco, Bond Lisa M., McKerracher Lisa, Vaccaro Alexander R., and Okonkwo David O.

Published Online: 1 May 2018 | <https://doi.org/10.1089/neu.2017.5434>

Sections View Article

Tools Share

초 록

안 내

자료 및 연구방법

결 론

Abstract

View PDF

PDF 보기

Introduction

View PDF Plus

Methods

Conclusions

Acknowledgments

Author Disclosure Statement

즐거 찾기

참고문헌 다운

참고문헌 보기

Publication으로
돌아가기

Add to favorites

Download Citations

Track Citations

Back To Publication



Facebook



Twitter



LinkedIn



Google+ Share



Reddit



Email

각종 SNS와 이메일
로 공유 가능



VOLUME 35, ISSUE 9

MAY 2018

Information

© Michael G. Fehlings et al.

Michael G. Fehlings, Rizzo Marco, Bond Lisa M., McKerracher Lisa, Vaccaro Alexander R., and Okonkwo David O.

Journal of Neurotrauma. May 2018. ahead of print
DOI: 10.1089/neu.2017.5434

Volume: 35 Issue 9: May 1, 2018
Date of Print: March 1, 2018
Date of Editing: January 9, 2018

Keywords

motor recovery

Rho inhibition

spinal cord injury

SPRING trial

VX-210

Publication History

Published online 1 May 2018



Rho Inhibitor VX-210 in Acute Traumatic Subaxial Cervical Spinal Cord Injury: Design of the SPinal Cord Injury Rho INhibition InvestiGation (SPRING) Clinical Trial

Fehlings Michael G. ✉ Kim Kee D., Aarabi Bizhan, Rizzo Marco, Bond Lisa M., McKerracher Lisa, Vaccaro Alexander R., and Okonkwo David O.

Published Online: 1 May 2018 | <https://doi.org/10.1089/neu.2017.5434>

Sections View Article

Tools Share

Abstract

Traumatic spinal cord injury (SCI) is associated with a lifetime of disability stemming from loss of motor, sensory, and autonomic functions; these losses, along with increased comorbid sequelae, negatively impact health outcomes and quality of life. Early decompression surgery post-SCI can enhance patient outcomes, but does not directly facilitate neural repair and regeneration. Currently, there are no U.S. Food and Drug Administration–approved pharmacological therapies to augment motor function and functional recovery in individuals with traumatic SCI. After an SCI, the enzyme, Rho, is activated by growth-inhibitory factors and regulates events that culminate in collapse of the neuronal growth cone, failure of axonal regeneration, and, ultimately, failure of motor and functional recovery. Inhibition of Rho activation is a potential treatment for injuries such as traumatic SCI. VX-210, an investigational agent, inhibits Rho. When administered extradurally after decompression (corpectomy or laminectomy) and stabilization surgery in a phase 1/2a study, VX-210 was well tolerated. Here, we describe the design of the SPRING trial, a multicenter, phase 2b/3, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of VX-210 (NCT02669849). A subset of patients with acute traumatic cervical SCI is currently being enrolled in the United States and Canada. Medical, neurological, and functional changes are evaluated at 6 weeks and at 3, 6, and 12 months after VX-210 administration. Efficacy will be assessed by the primary outcome measure, change in upper extremity motor score at 6 months post-treatment, and by secondary outcomes that include question-based and task-based evaluations of functional recovery.




FIG. 1. SCI-mediated Rho (A) activation and (B) inhibition by VX-210. CSPG, chondroitin sulfate proteoglycan; MAG, myelin-associated glycoprotein; Nogo-A, neurite outgrowth inhibitory protein A; OMgp, oligodendrocyte-myelin glycoprotein; RGM, repulsive guidance molecule; TNF, tumor necrosis factor.



Rho Inhibitor VX-210 in Acute Traumatic Subaxial Cervical Spinal Cord Injury: Design of the SPinal Cord Injury Rho INhibition InvestiGation (SPRING) Clinical Trial

Fehlings Michael G. , Kim Kee D., Aarabi Bizhan, Rizzo Marco, Bond Lisa M., McKerracher Lisa, Vaccaro Alexander R., and Okonkwo David O.

Published Online: 1 May 2018 | <https://doi.org/10.1089/neu.2017.5434>

 Sections  View Article

 Tools  Share

Abstract

Traumatic spinal cord injury (SCI) is associated with a lifetime of disability stemming from loss of motor, sensory, and autonomic functions; these losses, along with increased comorbid sequelae, negatively impact health outcomes and quality of life. Early decompression surgery post-SCI can enhance patient outcomes, but does not directly facilitate neural repair and regeneration. Currently, there are no U.S. Food and Drug Administration–approved pharmacological therapies to augment motor function and functional recovery in individuals with traumatic SCI. After an SCI, the enzyme, Rho, is activated by growth-inhibitory factors and regulates events that culminate in collapse of the neuronal growth cone, failure of axonal regeneration, and, ultimately, failure of motor and functional recovery. Inhibition of Rho activation is a potential treatment for injuries such as traumatic SCI. VX-210, an investigational agent, inhibits Rho. When administered extradurally after decompression (corpectomy or laminectomy) and stabilization surgery in a phase 1/2a study, VX-210 was well tolerated. Here, we describe the design of the SPRING trial, a multicenter, phase 2b/3, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of VX-210 (NCT02669849). A subset of patients with acute traumatic cervical SCI is currently being enrolled in the United States and Canada. Medical, neurological, and functional changes are evaluated at 6 weeks and at 3, 6, and 12 months after VX-210 administration. Efficacy will be assessed by the primary outcome measure, change in upper extremity motor score at 6 months post-treatment, and by secondary outcomes that include question-based and task-based evaluations of functional recovery.

References

1 National Spinal Cord Injury Statistical Center. Spinal cord injury facts and figures at a glance. 2017. Available at: <https://www.nscisc.uab.edu>. Accessed July 14, 2017.

2 SinghA., TetreaultL., Kalsi-RyanS., NouriA., and FehlingsM.G. (2014). Global prevalence and incidence of traumatic spinal cord injury. **Clin. Epidemiol.** 6, 309–331. Medline

3 AarabiB., SansurC.A., IbrahimiD.M., SimardJ.M., HershD.S., LeE., DiazC., MassettiJ., and Akhtar-DaneshN. (2017). Intramedullary lesion length on postoperative magnetic resonance imaging is a strong predictor of ASIA impairment scale grade conversion following decompressive surgery in cervical spinal cord injury. **Neurosurgery** 80, 610–620. Crossref, Medline

4 World Health Organization. Spinal cord injury: fact sheet no. 384. 2013. Available at: <http://www.who.int/mediacentre/factsheets/fs384/en/>. Accessed July 14, 2017.

5 FehlingsM.G., VaccaroA., WilsonJ.R., SinghA., CadotteD.W., HarropJ.S., AarabiB., ShaffreyC., DvorakM., FisherC., ArnoldP., MassicotteE.M., LewisJ., and RampersaudR. (2012). Early versus





Rho Inhibitor VX-210 in Acute Traumatic Subaxial Cervical Spinal Cord Injury: Design of the SPinal Cord Injury Rho INhibition InvestiGation (SPRING) Clinical Trial

Fehlings Michael G. Kim Kee D., Aarabi Bizhan, Rizzo Marco, Bond Lisa M., McKerracher Lisa, Vaccaro Alexander R., and Okonkwo David O.

Published Online: 1 May 2018 | <https://doi.org/10.1089/neu.2017.5434>

Sections View Article

Tools Share

Abstract

Traumatic spinal cord injury (SCI) is associated with a lifetime of disability stemming from loss of motor, sensory, and autonomic functions; these losses, along with increased comorbid sequelae, negatively impact health outcomes and quality of life. Early decompression surgery post-SCI can enhance patient outcomes, but does not directly facilitate neural repair and regeneration. Currently, there are no U.S. Food and Drug Administration–approved pharmacological therapies to augment motor function and functional recovery in individuals with traumatic SCI. After an SCI, the enzyme, Rho, is activated by growth-inhibitory factors and regulates events that culminate in collapse of the neuronal growth cone, failure of axonal regeneration, and, ultimately, failure of motor and functional recovery. Inhibition of Rho activation is a potential treatment for injuries such as traumatic SCI. VX-210, an investigational agent, inhibits Rho. When administered extradurally after decompression (corpectomy or laminectomy) and stabilization surgery in a phase 1/2a study, VX-210 was well tolerated. Here, we describe the design of the SPRING trial, a multicenter, phase 2b/3, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of VX-210 (NCT02669849). A subset of patients with acute traumatic cervical SCI is currently being enrolled in the United States and Canada. Medical, neurological, and functional changes are evaluated at 6 weeks and at 3, 6, and 12 months after VX-210 administration. Efficacy will be assessed by the primary outcome measure, change in upper extremity motor score at 6 months post-treatment, and by secondary outcomes that include question-based and task-based evaluations of functional recovery.

Recommended

Rodent Neural Progenitor Cells Support Functional Recovery after Cervical Spinal Cord Contusion

Brock John HoffmanGraham LoriStaufenberg Eileen Im SarahTuszynski Mark Henry

VOL. 35, NO. 9, MAY 2018

A Community Perspective on Bowel Management and Quality of Life after Spinal Cord Injury: The Influence of Auto ...

Inskip Jessica A.Lucci Vera-Ellen M. McGrath Maureen S.Willms Rhonda ...

VOL. 35, NO. 9, MAY 2018

Predicting Injury Severity and Neurological Recovery after Acute Cervical Spinal Cord Injury: A Comparison of Cerebrospinal Flui ...

Dalkilic TurkerFallah NaderNoonan Vanessa K. Salimi Elizei SanamDong KevinBelanger Lise ...

VOL. 35, NO. 3, FEBRUARY 2018

Xenon Protects against Blast-Induced Traumatic Brain Injury in an *In Vitro* Model

Campos-Pires RitaKoziakova MariiaYonis Amina Pau AshniMacdonald WarrenHarris Katie ...

VOL. 35, NO. 8, APRIL 2018



Mary Ann Liebert, Inc.  publishers

**Biotechnology
and
Regenerative
Medicine**



**Biomedical
Research**



**Clinical
Medicine**



**Engineering
and
Technology**



**Environmental Studies
Integrative Medicine
Law and Policy
Nursing
Public Health
Surgery**



Thank you !

www.ebsco.co.kr

TEL: 02-598-2571

